Topically administered strontium-containing complexes for treating pain, pruritis and inflammation
Therapeutically-active compositions that combine strontium with at least one additional molecules that increase the overall therapeutic potency of the combination beyond the potency of any of the separate constituents. Specifically, the combinations perform two important functions; (1) they increase the ability of topically-applied strontium to inhibit both acute sensory irritation (e.g., pruritus and pain), redness, swelling and inflammation (collectively defined for purposes of this description, “irritation”) and the chronic irritation that is characteristic of and contributes to the development and maintenance of painful or pruritic neuropathic conditions; and (2) they decrease the strontium activated pathways that are known to enhance the development and maintenance of pain, pruritis and neuropathic conditions.
1 . A method of treating pruritis in a subject, the method comprising topically administering to the subject a composition comprising a complex of:
a divalent cationic strontium moiety;
a cysteine-based anti-oxidant moiety selected from the group consisting of cysteine, N-acetyl cysteine, N-acetyl cysteinate, N,S-diacetylcysteine, and esters thereof; and
a polyhydroxyphenol moiety selected from the group consisting of gallic acid, caffeic acid, quercetin, luteolin, epigallocatechin gallate, epigallocatechin, epicatechin gallate, genistein, myricetin, and esters thereof;
in a suitable carrier vehicle,
wherein the cysteine-based anti-oxidant moiety and the polyhydroxyphenol moiety are conjugated together by a cleavable bond.
2 . The method of claim 1 , wherein the divalent cationic strontium moiety is a strontium salt selected from the group consisting of strontium chloride, strontium chloride hexahydrate, strontium sulfate, strontium carbonate, strontium nitrate, strontium hydroxide, strontium hydrosulfide, strontium oxide, strontium acetate, strontium glutamate, strontium aspartate, strontium malonate, strontium maleate, strontium citrate, strontium threonate, strontium lactate, strontium pyruvate, strontium ascorbate, strontium alpha-ketoglutarate, and strontium succinate.
3 . The method of claim 1 , wherein the cysteine-based anti-oxidant moiety is N-acetyl cysteine or esters thereof.
4 . The method of claim 1 , wherein the polyhydroxyphenol moiety is gallic acid or esters thereof.
5 . The method of claim 1 , wherein the cysteine-based anti-oxidant moiety is N-acetyl cysteine or esters thereof and the polyhydroxyphenol moiety is gallic acid or esters thereof.
6 . The method of claim 1 , wherein the cleavable bond is selected from the group consisting of a peptide bond, an ester bond, a thioester bond, an enzymatically cleavable bond, a disulfide bond, and a pH dependent bond.
7 . The method of claim 6 , wherein the cleavable bond is a thioester bond.
8 . The method of claim 1 , wherein the composition further comprises a polymer.
9 . The method of claim 8 , wherein the polymer is selected from the group consisting of polyvinylpyrrolidone, cyclodextrins, carrageenan, alginic acid, xanthan gum, sulfated polysaccharides, pentosane polysulfate, chondroitin sulfate, dextran sulfate, and heparin sulfate.
10 . A method of treating pruritis in a subject, the method comprising topically administering to the subject a composition comprising a complex of:
a divalent cationic strontium moiety;
a cysteine-based anti-oxidant moiety; and
a polyhydroxyphenol moiety;
wherein the cysteine-based anti-oxidant moiety and the polyhydroxyphenol moiety are conjugated together by a thioester bond.
11 . The method of claim 10 , wherein the divalent cationic strontium moiety is a strontium salt selected from the group consisting of strontium chloride, strontium chloride hexahydrate, strontium sulfate, strontium carbonate, strontium nitrate, strontium hydroxide, strontium hydrosulfide, strontium oxide, strontium acetate, strontium glutamate, strontium aspartate, strontium malonate, strontium maleate, strontium citrate, strontium threonate, strontium lactate, strontium pyruvate, strontium ascorbate, strontium alpha-ketoglutarate, and strontium succinate.
12 . The method of claim 10 , wherein the cysteine-based anti-oxidant moiety is N-acetyl cysteine or esters thereof.
13 . The method of claim 10 , wherein the polyhydroxyphenol moiety is gallic acid or esters thereof.
14 . The method of claim 10 , wherein the cysteine-based anti-oxidant moiety is N-acetyl cysteine or esters thereof and the polyhydroxyphenol moiety is gallic acid or esters thereof.
15 . The method of claim 10 , wherein the composition further comprises a polymer.
16 . The method of claim 15 , wherein the polymer is selected from the group consisting of polyvinylpyrrolidone, cyclodextrins, carrageenan, alginic acid, xanthan gum, sulfated polysaccharides, pentosane polysulfate, chondroitin sulfate, dextran sulfate, and heparin sulfate.
17 . A method of treating pruritis in a subject, the method comprising topically administering to the subject a composition comprising a complex of:
a strontium nitrate moiety;
an N-acetyl cysteine moiety; and
a gallic acid moiety;
wherein the N-acetyl cysteine moiety and the gallic acid moiety are conjugated together by a thioester bond.
18 . The method of claim 17 , wherein the composition further comprises a polymer.
19 . The method of claim 18 , wherein the polymer is selected from the group consisting of polyvinylpyrrolidone, cyclodextrins, carrageenan, alginic acid, xanthan gum, sulfated polysaccharides, pentosane polysulfate, chondroitin sulfate, dextran sulfate, and heparin sulfate.